LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

Home・Akciju saraksts・Roivant Sciences Ltd

Roivant Sciences Ltd

Atvērts

SektorsVeselības aprūpe

29.6 -1.33

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.56

Max

30.08

Galvenie mērījumi
By Trading Economics
Ienākumi	-200M -314M
Pārdošana	428K 2M
Peļņas marža	-15,692.896
Darbinieki	750
EBITDA	-132M -290M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+24.43% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.9B 20B
Iepriekšējā atvēršanas cena	30.93
Iepriekšējā slēgšanas cena	29.6

Ziņu noskaņojums

By Acuity

24%

76%

43 / 345 Rangs Healthcare

Roivant Sciences Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. maijs 08:24 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026. g. 25. maijs 21:22 UTC

Peļņas

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026. g. 25. maijs 20:50 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:20 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:01 UTC

Tirgus saruna

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026. g. 25. maijs 14:43 UTC

Tirgus saruna

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026. g. 25. maijs 14:15 UTC

Tirgus saruna

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026. g. 25. maijs 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 25. maijs 12:58 UTC

Tirgus saruna

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026. g. 25. maijs 12:56 UTC

Tirgus saruna

Peļņas

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. maijs 12:34 UTC

Tirgus saruna

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026. g. 25. maijs 12:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero's Assets Look Strategic -- Market Talk

2026. g. 25. maijs 11:00 UTC

Tirgus saruna

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026. g. 25. maijs 10:19 UTC

Tirgus saruna

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026. g. 25. maijs 10:05 UTC

Peļņas

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026. g. 25. maijs 10:04 UTC

Peļņas

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026. g. 25. maijs 10:03 UTC

Peļņas

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026. g. 25. maijs 10:02 UTC

Peļņas

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026. g. 25. maijs 10:01 UTC

Peļņas

Tenaga Nasional 1Q Net Up 3.7% on Year

2026. g. 25. maijs 10:00 UTC

Peļņas

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q EPS MYR0.1883

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Rev MYR17.1B

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Net MYR1.1B

2026. g. 25. maijs 09:38 UTC

Tirgus saruna

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026. g. 25. maijs 08:55 UTC

Tirgus saruna

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Salīdzinājums

Cenas izmaiņa

Roivant Sciences Ltd Prognoze

Cenas mērķis

By TipRanks

24.43% augšup

Prognoze 12 mēnešiem

Vidējais 37.28 USD 24.43%

Augstākais 42 USD

Zemākais 31.5 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Roivant Sciences Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Roivant Sciences Ltd — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

43 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.